Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Evoke Pharma Inc EVOK

Healthcare
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.


NDAQ:EVOK - Post by User

Evoke Pharma Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(232)
•••
Post by whytestockson Jun 17, 2024 1:45pm
40 Views
Post# 36092458

Evoke Pharma Reports Commercial Strategy Progress & Positive

Evoke Pharma Reports Commercial Strategy Progress & Positive
News; $EVOK Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI | BenzingaExpanded State Medicaid Access for GIMOTIAchieved highest ever monthly GIMOTI prescription fills in May 2024Promoted former VP of Finance, Mark ...EVOK - Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI | Benzinga




<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities